Afyx Therapeutics A/S — Credit Rating and Financial Key Figures
CVR number: 38793594
Agern Alle 24, 2970 Hørsholm
cm@inphena.com
tel: 71747174
www.inphena.com
Income statement (kDKK)
2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | -1 134.30 | - 585.93 | 1 509.14 | -3 345.74 | 6 404.98 |
| Employee benefit expenses | - 434.96 | - 720.98 | -1 971.80 | -2 302.02 | -4 174.10 |
| Other operating expenses | -5 315.72 | ||||
| Total depreciation | - 317.85 | - 561.89 | -1 010.20 | -1 270.90 | |
| EBIT | -1 569.27 | -1 624.76 | -1 024.55 | -6 657.95 | -4 355.74 |
| Other financial income | 7.36 | ||||
| Other financial expenses | -0.39 | -65.29 | - 144.95 | -61.23 | - 215.23 |
| Reduction non-current investment assets | -23.39 | ||||
| Net income from associates (fin.) | -75.00 | ||||
| Pre-tax profit | -1 569.66 | -1 690.05 | -1 185.52 | -6 719.19 | -4 645.97 |
| Income taxes | 183.40 | 371.34 | -1 150.37 | 2 392.72 | |
| Net earnings | -1 569.66 | -1 506.65 | - 814.18 | -7 869.56 | -2 253.25 |
Assets (kDKK)
2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Development expenditure | 1 628.68 | 3 613.17 | 4 739.21 | 5 502.84 | 5 535.47 |
| Intangible assets total | 1 628.68 | 3 613.17 | 4 739.21 | 5 502.84 | 5 535.47 |
| Tangible assets total | |||||
| Holdings in group member companies | 23.39 | 19.80 | |||
| Other receivables | 101.92 | 306.70 | |||
| Investments total | 23.39 | 101.92 | 326.50 | ||
| Long term receivables total | |||||
| Finished products/goods | 786.63 | ||||
| Inventories total | 786.63 | ||||
| Current trade debtors | 1.95 | 878.68 | 1 162.99 | 421.70 | 3 139.95 |
| Current amounts owed by group member comp. | 1 054.49 | 2 379.53 | 0.00 | ||
| Current owed by particip. interest comp. | 74.10 | ||||
| Prepayments and accrued income | 17.77 | 205.86 | |||
| Current other receivables | 101.79 | 302.06 | 640.87 | 346.94 | 514.57 |
| Current deferred tax assets | 2 418.17 | ||||
| Short term receivables total | 177.84 | 2 235.23 | 4 183.40 | 786.40 | 6 278.55 |
| Cash and bank deposits | 466.08 | 223.21 | 853.63 | 5 665.34 | 2 899.09 |
| Cash and cash equivalents | 466.08 | 223.21 | 853.63 | 5 665.34 | 2 899.09 |
| Balance sheet total (assets) | 2 272.60 | 6 095.00 | 9 776.24 | 12 056.50 | 15 826.24 |
Equity and liabilities (kDKK)
2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Share capital | 813.70 | 1 205.70 | 3 566.70 | 3 566.70 | 4 566.70 |
| Share premium account | 7 000.00 | ||||
| Other reserves | 1 628.68 | 2 818.27 | 3 696.58 | 4 292.21 | 4 317.67 |
| Retained earnings | 159.40 | 2 178.70 | - 206.26 | -1 020.44 | -8 890.00 |
| Profit of the financial year | -1 569.66 | -1 506.65 | - 814.18 | -7 869.56 | -2 253.25 |
| Shareholders equity total | 1 032.12 | 4 696.03 | 6 242.85 | -1 031.08 | 4 741.12 |
| Provisions | 4 104.56 | ||||
| Non-current owed to participating | 999.00 | ||||
| Non-current liabilities total | 999.00 | ||||
| Current trade creditors | 23.00 | 30.00 | 60.00 | 1 838.05 | 4 940.65 |
| Current owed to group member | 1 058.94 | 2 394.48 | 11 094.16 | 1 479.61 | |
| Other non-interest bearing current liabilities | 218.48 | 310.03 | 1 078.92 | 155.38 | 560.31 |
| Current liabilities total | 241.48 | 1 398.97 | 3 533.39 | 13 087.59 | 6 980.56 |
| Balance sheet total (liabilities) | 2 272.60 | 6 095.00 | 9 776.24 | 12 056.50 | 15 826.24 |
Try the full version of our system for free
Create your own estimates for any company
Valuation analysis
See instructions
... and more!
No registration needed.